An interventional study of Goat milk-based infant formula and Cow's milk-based infant formula in Gastrointestinal Tolerance, Gastrointestinal Symptoms and Infections, sponsored by Ausnutria Hyproca B.V.. Recruiting at 1 site in Saudi Arabia. Open to participants aged 14 Days to 90 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Ausnutria Hyproca B.V. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This randomized controlled double-blind study will compare the effect of a commercially available goat milk formula to a cow's milk formula on gastrointestinal symptoms and tolerance, and infections in infants.
2,097 studies on the registry are indexed under Infections; 361 are open to participants now.
This study's planned enrollment of 144 is above the median of 113 across 1,305 interventional studies indexed under Infections.
Browse Infections studies →Ausnutria Hyproca B.V. is the lead sponsor of 6 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Goat milk-based infant formula
Other: Goat milk-based infant formula
Cow's milk-based infant formula
Other: Cow's milk-based infant formula
Study product is administered on demand until the age of 6 months.
Study product is administered on demand until the age of 6 months.
Gastrointestinal symptoms as determined by CoMiSS
The CoMiSS® is a simple, fast, and easy-to-use awareness tool for cow's milk-related symptoms and may be used in clinical trials to evaluate and quantify the severity of symptoms during a feeding trial. The CoMiSS scores symptoms in five different domains: Crying, Regurgitation, Stools, Skin and Respiratory. The CoMiSS score ranges from 0 to 33 with score 0 as best score (no symptoms) and 33 as worst score (severe symptoms).
Time frame: Difference between groups at Day 14 of the intervention
Gastrointestinal tolerance as determined by IGSQ
The IGSQ is a 13-item self-report instrument that has been used in clinical trials to assess infants' GI-related signs and symptoms observed by their parents over the previous week in 5 domains: stooling, regurgitation/vomiting, flatulence, crying, and fussiness. The IGSQ has a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress.
Time frame: Difference between groups at the end of the intervention at 24 weeks
Gastrointestinal symptoms throughout the study as determined by CoMiSS
The CoMiSS® is a simple, fast, and easy-to-use awareness tool for cow's milk-related symptoms and may be used in clinical trials to evaluate and quantify the severity of symptoms during a feeding trial. The CoMiSS scores symptoms in five different domains: Crying, Regurgitation, Stools, Skin and Respiratory. The CoMiSS score ranges from 0 to 33 with score 0 as best score (no symptoms) and 33 as worst score (severe symptoms).
Time frame: From enrollment to the end of the intervention at 24 weeks
Gastrointestinal tolerance throughout the study as determined by IGSQ
The IGSQ is a 13-item self-report instrument that has been used in clinical trials to assess infants' GI-related signs and symptoms observed by their parents over the previous week in 5 domains: stooling, regurgitation/vomiting, flatulence, crying, and fussiness. The IGSQ has a possible range of 13 to 65, where higher values indicate greater GI distress and values ≤ 23 indicate no digestive distress.
Time frame: From enrollment to the end of the intervention at 24 weeks
Occurrence, duration and severity of gastrointestinal infections as determined by Vesikari
The Vesikari Clinical Severity Scoring System includes a e-diary card completed by parents, to identify rotavirus gastroenteritis episodes. The Vesikari Clinical Severity Scoring System Parameters score ranges from 0 to 20 with score \<7 as mild symptoms and score 10 to 20 as severe symptoms.
Time frame: From enrollment to the end of the intervention at 24 weeks
Occurrence, duration and severity of respiratory infections as determined by CARIFS
Canadian Acute Respiratory Illness and Flu Scale is a validated parental questionnaire, to measure the disease severity of children with acute respiratory illness (ARI) including influenza. CARIFS consists of 18 items covering three domains; symptoms (e.g., cough); function (e.g., play), and parental impact (e.g., clinginess). Each item is scored 0 to 3, with higher scores indicating greater severity of illness. The full scale ranges from 0 to 58. For children older than 5 years the full scale is used; for children younger than 5 years, 3 items (headache, sore throat, and muscle aches) are not used for assessment.
Time frame: From enrollment to the end of the intervention at 24 weeks
Occurrence, duration and severity of ear infections as determined by AOM-SOS V5
The Acute Otitis Media Symptom Severity scale (AOM-SOS) Version 5.0 is psychometric scale used to measure the severity of symptoms in children with acute otitis media and has been validated for parent-reported use. A 6-point Likert scale ranging from 'No' to 'An extreme amount' is used to rate the presence of 5 symptoms related to acute otitis media over the preceding 24 hours. The AOM-SOS Version 5.0 total score is obtained by summing the scores on these 5 equally-weighted questions.
Time frame: From enrollment to the end of the intervention at 24 weeks
Quality of life as determined by PedsQL
The Pediatric Quality of Life Inventory (PedsQL™) Infant Scales™ is a specific module of the PedsQL™. The objective of this validated questionnaire is to measure generic health-related quality of life in infants. Applicable for infants with acute and chronic health conditions and healthy infants. The questionnaire is composed of 36 items comprising 5 dimensions: physical functioning, physical symptoms, emotional functioning, social functioning and cognitive functioning. Higher scores means better HRQOL and fewer problems or symptoms. A 5-point Likert scale from is applied: 0 (Never) to 4 (Almost always). Scores are transformed on a scale from 0 to 100.
Time frame: From enrollment to the end of the intervention at 24 weeks
Quality of life as determined by WHOQoL-BREF
The World Health Organization Quality of Life Questionnaire BREF (WHOQoL-BREF) is the shortened version of the WHOQoL-100. The WHOQoL-BREF measures quality of life within the context of an individual's culture, value systems, personal goals, standards of concerns. The measuring instrument consists of 26 items. The raw scoreis transformed to a 0-100 scale, where higher scores indicate higher perceived quality of life.
Time frame: From enrollment to the end of the intervention at 24 weeks
Weight
Weight will be measured in kilograms.
Time frame: From enrollment to the end of the intervention at 24 weeks
Height
Height will be measured in centimeters.
Time frame: From enrollment to the end of the intervention at 24 weeks
Head circumference
Head circumference will be measured in centimeters.
Time frame: From enrollment to the end of the intervention at 24 weeks
WHO z-scores
Subject's weight, length and head circumference will be used to calculate the WHO z-scores for weight-for-age, length-for-age, head circumference-for-age, weight-for-length.
Time frame: From enrollment to the end of the intervention at 24 weeks
Fecal parameters
The major fecal bacterial groups are defined using 16S RNA sequencing. Further fecal parameters (e.g. pH, SCFA, sIgA, A1AT) are determined with standard laboratory techniques.
Time frame: Baseline, Day 14, Day 28, Week 12 and Week 24
Sleep and Crying episodes
Sleep and crying episodes and duration are recorded for 24 hours prior to the visits in diaries.
Time frame: Baseline, Day 14, Day 28, Week 12 and Week 24
Stool frequency & consistenty
Stool frequency and consistency are recorded for 24 hours prior to visits in diaries.
Time frame: Baseline, Day 14, Day 28, Week 12 and Week 24
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2026 (actual). Primary completion is estimated for Sep 2027, 13 months after the start.
Of 308 interventional studies with no phase under Infections, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 48. This study's planned 13 months is below that.
Infections covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Aug 2026, on Nov 18, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ausnutria Hyproca B.V.